U.S. Markets closed

Aratana Therapeutics, Inc. (PETX)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
7.06-0.13 (-1.81%)
At close: 4:00PM EDT
People also watch
OMEROMEDPTCTOCULKPTI
  • AT-003 Nocita for cats - pivotal study results any time now!
    Entyce CMC approval - any time now!

    Do we have to wait for August 4th for the quarterly conference call to get some news! Two more weeks.
  • Take this as it is. Just checked a Vet forum I am part of and there was a new thread on Galliprant. About 70 or so responses from vets using it across the country. A large majority were very positive as far as results (roughly 60 positive experiences to about 10 negative). Biggest complaint is price and varying backordered situations. In some places the 100mg tabs are still backordered due to breaking of the tablets in the container.

    Looking forward, I think the sales results will continue to improve. Don't anticipate too much from adding cats to the Nocita label. Unless they change the indication, CCL repair is not very common in cats. And Nocita is just barely making a dent in the canine market. Might see some benefit if the label for cats includes different procedures. Mainly waiting on Entyce - nothing out there is even close. I have about 20-30 patients right now in my head that would greatly benefit from it. Hope it's out soon.

    Again - just a little from what I'm hearing- take it or leave it.
  • Galliprant is now on backorder at my vet. #$%$? My 10 yr old dobie has been doing great on it for last 40 days. We have never been able to pet or touch his backside from problems during two surgeries he's had as a puppy. Now he loves to be massaged there. He's taking 100mg. They have 7 left and will give us those but come on aratana. i know you're new at this but get it together.
  • We need some news! This is getting boring, but that being said, the stock is holding up very nicely.

    European approval - Don't know when, it's under Elanco control. So, if they get aggressive on the labeling, it could take a while.
    AT-003 Nocita for cats - pivotal study results any time now!
    Entyce CMC approval - I am looking for this sometime in the next 5 weeks. This is important, because PETX committed to a fall launch. We want that to be Labor Day! Get some Q.3 Entyce revenues.
    June quarterly financials - should be around August 2nd. We will see the revenue growth continue.

    Good luck to all.
  • Check out the Volume Monday on ACRX 26 x average... Aratana, buyout offer from Eli Lilly someday...?
  • I'm looking for 10+
  • Another nice Seeking Alpha article this morning. I suspect the stock will continue to rise throughout the day now. It was a Veterinarian that wrote it. The appropriately dinged the company on it's manufacturing mistakes, but that could all be in the past now.

    I'm still looking for 10+ by year end, with another 60% beyond that sometime in 2018.
  • Off topic, maybe?... Another animal welfare co I follow KIN announced today that they acquired a manufacturing plant in Elwood KS, PETX is headquartered in Leawood KS which is only about 60 miles away per my crude analysis. I don't know if we can connect any dots here but this is close to home IMO. Is KIN a potential suitor? I don't know but wanted to chime in as there may be a connection here or maybe not, any conspiracy theories welcome, lol... GL PETX longs!
  • Chart update: Now that we have clearly broken the $7 mark (which was pretty strong resistance) it should now become support. There are some additional resistance levels above $7 but with less shares traded at these levels they should be easier to break through. Don't know exactly where PETX will go from here but onward and upward looks to be the case. JMHO
  • Over a million shares traded on Friday! Given that the Biotechnology indexes had gone up so much last week, PETX should have gone up even more than it did. So, at least we can say that we are losing all of the nonbelievers. Plenty of room for everybody who wants out. I think, OK maybe I should say I hope, that this allows for an even bigger gain when they announce the first of several good news milestones that should be coming out over the next couple of months. Good luck to all longs.
  • http://www.bizjournals.com/kansascity/news/2017/06/30/fast-50-no-1-aratana-therapeutics.html

    KC’s fastest-growing businesses: No. 1 Aratana Therapeutics - Kansas City Business Journal
    The Leawood animal pharmaceuticals company lands atop our Fastest-Growing Area Businesses List, with average annual revenue growth of 2,791 percent from 2014-2016.
    www.bizjournals.com
  • The trading setup for PETX looks very enticing. I started receiving notifications from AWE.some.STOCK_S the other week and so far they have presented interesting new trade ideas.
  • IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL

    Intelgenx (IGXT)

    MarketCap $50 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.80

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017

    http://www.biotuesdays.com/features/2017/5/11/intelgenx-has-multi-faceted-bd-approach-for-its-oral-films

    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

    IntelGenx has multi-faceted BD approach for its oral films
    With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
    www.biotuesdays.com
  • Chart wise if we break $7 and can hold it then upward momentum should follow... Interesting times w/chart and timing of upcoming events. Holding, like some of you have mentioned $10 by year end may come sooner than later, JMHO.
  • Also, just noticed on Yahoo stats for PETX that over 15% of shares are short, if that is true, could be good candidate for short squeeze since insiders own over the half the shares.
  • Happy to see that the future potential for this company and their field of expertise could be long term winner and finally getting some good upward movement in price per share. Go Long Aratana!
  • PETX is also benefitting from a market sector swing. Biotechs have not been on the favorites list and many are beaten down. With the economy looking like we won't have great growth, this sector is a better place to be. Also, the market has figured out that we won't have any crazy cuts to drug prices as Trumpcare is in limbo. Also, we should be seeing more M&A activity, and it will be a reminder that PETX is a great M&A target. I really think we are going to see higher and higher 12 month targets from analysts. It has taken a long time, but this is definitely starting to turn the corner.
  • Up $.35 on over 400 thousand shares on a no news day. The high volume of shares makes it more real. No reason why this stock shouldn't keep going. The executive has gotten the word out that the future is bright! Plenty of upcoming milestones to keep this moving in the right direction.
  • Positive column in Seeking Alpha published last night. Title is "Aratana: Why You Might Want To Grab A Few Shares In This Rapidly Expanding Companion Animal Market". No great new insight, just the story we all know packaged up. Hopefully it will alert the unwashed masses to PETX!
  • Last stop: William Blair 2017 Growth Stock Conference in Chicago
    Wednesday, June 14, 2017 at 9:40 a.m. ET

    It would be nice if they had something else new to talk about. Entyce status update? Nocita for cats approval? Too early for other anouncements.